| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 103 | 2026 | 825 | 18.990 |
Why?
|
| Cystadenocarcinoma, Serous | 12 | 2026 | 69 | 4.390 |
Why?
|
| Tumor Microenvironment | 25 | 2025 | 617 | 3.560 |
Why?
|
| Neoplasm Metastasis | 23 | 2025 | 1089 | 2.520 |
Why?
|
| Adipocytes | 7 | 2023 | 180 | 2.440 |
Why?
|
| Peritoneal Neoplasms | 15 | 2025 | 195 | 2.360 |
Why?
|
| Neoplasms, Glandular and Epithelial | 12 | 2017 | 79 | 2.070 |
Why?
|
| Omentum | 12 | 2025 | 69 | 2.060 |
Why?
|
| Nicotinamide N-Methyltransferase | 3 | 2026 | 10 | 2.010 |
Why?
|
| Cancer-Associated Fibroblasts | 5 | 2025 | 44 | 1.940 |
Why?
|
| Cell Line, Tumor | 49 | 2025 | 2888 | 1.910 |
Why?
|
| Adnexal Diseases | 3 | 2025 | 23 | 1.830 |
Why?
|
| Female | 140 | 2026 | 51535 | 1.780 |
Why?
|
| Proteomics | 9 | 2025 | 279 | 1.690 |
Why?
|
| Cancer Survivors | 3 | 2023 | 108 | 1.630 |
Why?
|
| Proto-Oncogene Proteins c-met | 11 | 2015 | 199 | 1.560 |
Why?
|
| Gene Expression Regulation, Neoplastic | 25 | 2025 | 1394 | 1.530 |
Why?
|
| Enzyme Inhibitors | 5 | 2026 | 642 | 1.530 |
Why?
|
| Drug Resistance, Neoplasm | 14 | 2024 | 665 | 1.490 |
Why?
|
| Metformin | 8 | 2025 | 132 | 1.470 |
Why?
|
| Humans | 173 | 2026 | 98076 | 1.440 |
Why?
|
| Fallopian Tubes | 6 | 2025 | 49 | 1.420 |
Why?
|
| Epithelial Cells | 14 | 2025 | 709 | 1.360 |
Why?
|
| Mice, Nude | 25 | 2020 | 830 | 1.340 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2025 | 60 | 1.320 |
Why?
|
| Mice | 50 | 2025 | 12698 | 1.320 |
Why?
|
| Neoplasm Invasiveness | 21 | 2025 | 582 | 1.290 |
Why?
|
| Urokinase-Type Plasminogen Activator | 11 | 2015 | 49 | 1.290 |
Why?
|
| MicroRNAs | 11 | 2023 | 604 | 1.240 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 2373 | 1.210 |
Why?
|
| Endometrial Neoplasms | 6 | 2025 | 242 | 1.190 |
Why?
|
| Animals | 71 | 2026 | 28894 | 1.170 |
Why?
|
| Neoplasms | 16 | 2026 | 3334 | 1.140 |
Why?
|
| High-Throughput Screening Assays | 3 | 2019 | 65 | 1.120 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2025 | 556 | 1.120 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2013 | 461 | 1.100 |
Why?
|
| Fallopian Tube Neoplasms | 4 | 2021 | 39 | 1.090 |
Why?
|
| Cytoreduction Surgical Procedures | 5 | 2025 | 105 | 1.020 |
Why?
|
| Cell Proliferation | 19 | 2025 | 1790 | 1.000 |
Why?
|
| Tumor Cells, Cultured | 22 | 2019 | 1028 | 0.990 |
Why?
|
| Fibronectins | 3 | 2014 | 104 | 0.990 |
Why?
|
| Carboplatin | 2 | 2025 | 331 | 0.960 |
Why?
|
| Adipose Tissue | 4 | 2022 | 280 | 0.930 |
Why?
|
| Naphthoquinones | 1 | 2025 | 8 | 0.910 |
Why?
|
| Proteogenomics | 1 | 2025 | 8 | 0.900 |
Why?
|
| 5-Methylcytosine | 2 | 2024 | 134 | 0.880 |
Why?
|
| Aniline Compounds | 1 | 2025 | 64 | 0.880 |
Why?
|
| Cell Adhesion | 16 | 2017 | 419 | 0.870 |
Why?
|
| Imidazoles | 2 | 2025 | 141 | 0.870 |
Why?
|
| Ovary | 5 | 2022 | 260 | 0.860 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2025 | 100 | 0.860 |
Why?
|
| Disease Progression | 16 | 2025 | 1610 | 0.850 |
Why?
|
| Fibroblasts | 8 | 2015 | 767 | 0.850 |
Why?
|
| Models, Biological | 5 | 2015 | 1807 | 0.830 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2025 | 212 | 0.820 |
Why?
|
| Paclitaxel | 3 | 2016 | 483 | 0.810 |
Why?
|
| Gene Expression Profiling | 7 | 2025 | 1565 | 0.790 |
Why?
|
| Glycerol | 1 | 2023 | 35 | 0.780 |
Why?
|
| Sulfonamides | 1 | 2025 | 351 | 0.760 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2025 | 337 | 0.740 |
Why?
|
| Extracellular Matrix | 4 | 2015 | 258 | 0.740 |
Why?
|
| Glycogen | 2 | 2019 | 58 | 0.720 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 116 | 0.720 |
Why?
|
| Coculture Techniques | 9 | 2020 | 175 | 0.720 |
Why?
|
| Tumor Burden | 6 | 2020 | 333 | 0.710 |
Why?
|
| Neoplasm Grading | 9 | 2025 | 422 | 0.670 |
Why?
|
| Antineoplastic Protocols | 1 | 2021 | 9 | 0.670 |
Why?
|
| Matrix Metalloproteinase 2 | 6 | 2009 | 48 | 0.670 |
Why?
|
| Cell Movement | 9 | 2019 | 814 | 0.660 |
Why?
|
| Signal Transduction | 17 | 2024 | 3620 | 0.650 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 25 | 0.650 |
Why?
|
| Carcinoma | 4 | 2015 | 440 | 0.640 |
Why?
|
| Neoplastic Stem Cells | 2 | 2024 | 189 | 0.620 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 473 | 0.620 |
Why?
|
| Mental Health | 2 | 2021 | 219 | 0.620 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 478 | 0.610 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 77 | 0.610 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 10 | 2013 | 20 | 0.600 |
Why?
|
| Epithelium | 8 | 2023 | 316 | 0.600 |
Why?
|
| Receptors, Cell Surface | 8 | 2007 | 291 | 0.600 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 2658 | 0.580 |
Why?
|
| Pandemics | 3 | 2022 | 916 | 0.580 |
Why?
|
| Liposomes | 2 | 2016 | 104 | 0.570 |
Why?
|
| Genomics | 3 | 2025 | 898 | 0.560 |
Why?
|
| Mutation | 12 | 2026 | 4392 | 0.560 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 663 | 0.550 |
Why?
|
| CD36 Antigens | 1 | 2018 | 15 | 0.540 |
Why?
|
| Transgender Persons | 1 | 2020 | 121 | 0.540 |
Why?
|
| Aged | 34 | 2025 | 21758 | 0.540 |
Why?
|
| Stress, Psychological | 1 | 2021 | 383 | 0.520 |
Why?
|
| Proteome | 4 | 2025 | 163 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 1535 | 0.510 |
Why?
|
| Middle Aged | 37 | 2025 | 29427 | 0.500 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 29 | 0.500 |
Why?
|
| Depression | 2 | 2021 | 615 | 0.500 |
Why?
|
| Biomarkers, Tumor | 13 | 2025 | 1764 | 0.490 |
Why?
|
| Integrin alpha5beta1 | 4 | 2011 | 11 | 0.490 |
Why?
|
| Promoter Regions, Genetic | 16 | 2015 | 977 | 0.470 |
Why?
|
| Blotting, Western | 9 | 2015 | 780 | 0.460 |
Why?
|
| Integrin alpha5 | 3 | 2013 | 5 | 0.450 |
Why?
|
| Transcription Factor AP-1 | 9 | 2007 | 68 | 0.450 |
Why?
|
| Cadherins | 4 | 2009 | 184 | 0.440 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 7389 | 0.440 |
Why?
|
| Matrix Metalloproteinase 9 | 8 | 2008 | 85 | 0.430 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 911 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1416 | 0.410 |
Why?
|
| Disease Models, Animal | 5 | 2013 | 2572 | 0.400 |
Why?
|
| Carcinogenesis | 3 | 2021 | 241 | 0.390 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 4 | 1997 | 85 | 0.390 |
Why?
|
| Molecular Targeted Therapy | 3 | 2025 | 321 | 0.390 |
Why?
|
| Ultrasonography | 3 | 2025 | 720 | 0.380 |
Why?
|
| Transcription Factors | 10 | 2025 | 1717 | 0.380 |
Why?
|
| Apoptosis | 7 | 2016 | 1752 | 0.380 |
Why?
|
| Hepatocyte Growth Factor | 6 | 2010 | 86 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2001 | 218 | 0.370 |
Why?
|
| Stromal Cells | 4 | 2019 | 153 | 0.370 |
Why?
|
| Spheroids, Cellular | 2 | 2017 | 31 | 0.370 |
Why?
|
| Adult | 29 | 2025 | 29538 | 0.370 |
Why?
|
| Hypoglycemic Agents | 4 | 2019 | 412 | 0.360 |
Why?
|
| Anoikis | 2 | 2011 | 7 | 0.360 |
Why?
|
| Extracellular Traps | 2 | 2025 | 17 | 0.360 |
Why?
|
| Neutrophils | 3 | 2025 | 346 | 0.350 |
Why?
|
| Cell Culture Techniques | 5 | 2017 | 196 | 0.350 |
Why?
|
| Transcriptome | 5 | 2025 | 820 | 0.350 |
Why?
|
| Ligands | 4 | 2025 | 486 | 0.350 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.350 |
Why?
|
| Salpingectomy | 1 | 2011 | 4 | 0.330 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2011 | 8 | 0.330 |
Why?
|
| Prognosis | 15 | 2019 | 4116 | 0.330 |
Why?
|
| Anilides | 1 | 2011 | 50 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 82 | 0.330 |
Why?
|
| Cell Survival | 5 | 2020 | 1014 | 0.330 |
Why?
|
| Cell Communication | 4 | 2018 | 222 | 0.330 |
Why?
|
| Ovariectomy | 1 | 2011 | 94 | 0.320 |
Why?
|
| Tissue Adhesions | 1 | 2011 | 55 | 0.320 |
Why?
|
| Hyaluronic Acid | 1 | 2011 | 48 | 0.320 |
Why?
|
| Quinolines | 1 | 2011 | 97 | 0.320 |
Why?
|
| Immunohistochemistry | 15 | 2020 | 1815 | 0.320 |
Why?
|
| BRCA1 Protein | 3 | 2026 | 222 | 0.320 |
Why?
|
| Glucose | 4 | 2023 | 704 | 0.320 |
Why?
|
| Vitronectin | 2 | 2008 | 4 | 0.320 |
Why?
|
| Estradiol | 1 | 2011 | 268 | 0.320 |
Why?
|
| Drug Synergism | 2 | 2025 | 317 | 0.320 |
Why?
|
| HIV Infections | 1 | 2020 | 1018 | 0.320 |
Why?
|
| Glycolysis | 4 | 2019 | 198 | 0.310 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 16 | 0.310 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.300 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 16 | 0.300 |
Why?
|
| Norethindrone | 1 | 2009 | 13 | 0.300 |
Why?
|
| Neuropeptides | 3 | 2004 | 113 | 0.300 |
Why?
|
| Indoles | 1 | 2011 | 334 | 0.300 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 551 | 0.300 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2001 | 215 | 0.300 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2021 | 88 | 0.300 |
Why?
|
| Up-Regulation | 6 | 2020 | 743 | 0.290 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 100 | 0.290 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2007 | 304 | 0.290 |
Why?
|
| Peritoneum | 3 | 2018 | 52 | 0.290 |
Why?
|
| RNA, Messenger | 10 | 2018 | 2063 | 0.280 |
Why?
|
| rac GTP-Binding Proteins | 3 | 2004 | 25 | 0.280 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 81 | 0.280 |
Why?
|
| Piperidines | 1 | 2010 | 172 | 0.280 |
Why?
|
| Methylation | 3 | 2025 | 294 | 0.280 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10972 | 0.280 |
Why?
|
| Pyridines | 2 | 2010 | 318 | 0.280 |
Why?
|
| Cells, Cultured | 7 | 2019 | 2855 | 0.270 |
Why?
|
| Transfection | 7 | 2015 | 883 | 0.270 |
Why?
|
| RNA, Small Interfering | 6 | 2019 | 564 | 0.270 |
Why?
|
| Integrin beta1 | 1 | 2007 | 36 | 0.270 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 1193 | 0.270 |
Why?
|
| Thrombin | 1 | 2007 | 60 | 0.260 |
Why?
|
| Colonic Neoplasms | 2 | 2025 | 582 | 0.260 |
Why?
|
| Homeodomain Proteins | 4 | 2014 | 566 | 0.260 |
Why?
|
| Histones | 3 | 2025 | 370 | 0.260 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 2080 | 0.250 |
Why?
|
| Keratins | 4 | 2007 | 62 | 0.250 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2025 | 64 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2019 | 301 | 0.240 |
Why?
|
| Antigens, Neoplasm | 2 | 2018 | 361 | 0.240 |
Why?
|
| Single-Cell Analysis | 3 | 2025 | 219 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 889 | 0.230 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 168 | 0.230 |
Why?
|
| Genome, Human | 2 | 2015 | 832 | 0.230 |
Why?
|
| Down-Regulation | 6 | 2020 | 529 | 0.230 |
Why?
|
| Alanine | 1 | 2025 | 82 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2025 | 53 | 0.220 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2025 | 31 | 0.220 |
Why?
|
| Amphiregulin | 1 | 2025 | 17 | 0.220 |
Why?
|
| DNA-Binding Proteins | 5 | 2025 | 1255 | 0.220 |
Why?
|
| Mass Spectrometry | 3 | 2022 | 191 | 0.220 |
Why?
|
| DNA Methylation | 5 | 2025 | 730 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 370 | 0.220 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2017 | 145 | 0.220 |
Why?
|
| Sensitivity and Specificity | 4 | 2023 | 1945 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 903 | 0.210 |
Why?
|
| Pyrazoles | 2 | 2020 | 160 | 0.210 |
Why?
|
| Pseudogenes | 1 | 2004 | 39 | 0.210 |
Why?
|
| Extracellular Vesicles | 2 | 2023 | 57 | 0.210 |
Why?
|
| BRCA2 Protein | 2 | 2026 | 177 | 0.210 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2024 | 15 | 0.210 |
Why?
|
| Lymphatic Metastasis | 3 | 2005 | 520 | 0.210 |
Why?
|
| Inflammation | 1 | 2011 | 1120 | 0.210 |
Why?
|
| Menopause | 1 | 2025 | 94 | 0.210 |
Why?
|
| Cell Cycle | 3 | 2011 | 518 | 0.210 |
Why?
|
| Interleukin-10 | 1 | 2025 | 167 | 0.200 |
Why?
|
| Menstrual Cycle | 1 | 2025 | 84 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 3598 | 0.200 |
Why?
|
| Breast Neoplasms | 6 | 2008 | 3272 | 0.200 |
Why?
|
| Genital Neoplasms, Female | 2 | 2016 | 118 | 0.200 |
Why?
|
| Glycerophosphates | 1 | 2023 | 8 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 2 | 2019 | 356 | 0.200 |
Why?
|
| Biomarkers | 3 | 2024 | 2020 | 0.200 |
Why?
|
| Laminin | 3 | 2001 | 89 | 0.200 |
Why?
|
| Phosphorylation | 6 | 2015 | 1145 | 0.200 |
Why?
|
| Adaptive Immunity | 1 | 2025 | 193 | 0.200 |
Why?
|
| Phosphoprotein Phosphatases | 3 | 2018 | 58 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 199 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2025 | 696 | 0.190 |
Why?
|
| Receptor Cross-Talk | 1 | 2023 | 32 | 0.190 |
Why?
|
| Survival Rate | 6 | 2017 | 2041 | 0.190 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 14 | 0.190 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 89 | 0.190 |
Why?
|
| Molecular Sequence Data | 9 | 2013 | 2896 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1286 | 0.190 |
Why?
|
| Collagenases | 5 | 2001 | 42 | 0.190 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 332 | 0.190 |
Why?
|
| Chromatography, Liquid | 2 | 2020 | 102 | 0.190 |
Why?
|
| Phosphates | 1 | 2023 | 165 | 0.190 |
Why?
|
| Obstetric Labor, Premature | 1 | 2023 | 57 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 4 | 2018 | 1110 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2020 | 108 | 0.180 |
Why?
|
| rac1 GTP-Binding Protein | 4 | 2009 | 47 | 0.180 |
Why?
|
| Postmenopause | 1 | 2022 | 109 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 291 | 0.180 |
Why?
|
| Gene Expression | 4 | 2016 | 1320 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 256 | 0.180 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 822 | 0.180 |
Why?
|
| Cell Growth Processes | 3 | 2015 | 83 | 0.180 |
Why?
|
| Lysophospholipids | 2 | 2019 | 67 | 0.180 |
Why?
|
| Heterografts | 2 | 2020 | 121 | 0.170 |
Why?
|
| Genes, ras | 3 | 1997 | 97 | 0.170 |
Why?
|
| Fatty Acids | 1 | 2022 | 147 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 176 | 0.170 |
Why?
|
| Protein Binding | 6 | 2013 | 1554 | 0.170 |
Why?
|
| Anxiety | 2 | 2021 | 370 | 0.170 |
Why?
|
| Leukocyte Elastase | 1 | 2021 | 8 | 0.170 |
Why?
|
| Hydrolases | 2 | 2018 | 30 | 0.170 |
Why?
|
| Platinum | 1 | 2021 | 68 | 0.170 |
Why?
|
| Premature Birth | 1 | 2023 | 131 | 0.170 |
Why?
|
| Transcriptional Activation | 5 | 2002 | 293 | 0.160 |
Why?
|
| Plasminogen | 1 | 2001 | 45 | 0.160 |
Why?
|
| Mice, Knockout | 4 | 2025 | 2207 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 1997 | 100 | 0.160 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 221 | 0.160 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2020 | 25 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-jun | 4 | 2007 | 34 | 0.160 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2020 | 36 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 2036 | 0.160 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 402 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2025 | 727 | 0.160 |
Why?
|
| Melanoma | 2 | 2022 | 524 | 0.160 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 53 | 0.150 |
Why?
|
| ras Proteins | 1 | 2001 | 137 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 63 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2019 | 54 | 0.150 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 31 | 0.150 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2001 | 164 | 0.150 |
Why?
|
| beta Catenin | 2 | 2014 | 267 | 0.150 |
Why?
|
| Endometriosis | 2 | 2011 | 67 | 0.150 |
Why?
|
| Amino Acid Sequence | 5 | 2018 | 2005 | 0.150 |
Why?
|
| Base Sequence | 9 | 2013 | 2222 | 0.150 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 375 | 0.150 |
Why?
|
| Enzymes | 1 | 2019 | 47 | 0.150 |
Why?
|
| Metabolomics | 1 | 2020 | 106 | 0.150 |
Why?
|
| Chromatin | 1 | 2022 | 454 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2023 | 3212 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2010 | 68 | 0.150 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2019 | 42 | 0.140 |
Why?
|
| Cell Death | 3 | 2021 | 257 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 280 | 0.140 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2009 | 13 | 0.140 |
Why?
|
| Transcription, Genetic | 6 | 2008 | 1133 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 64 | 0.140 |
Why?
|
| Hypertension | 1 | 2024 | 778 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 103 | 0.140 |
Why?
|
| Immunotherapy | 3 | 2020 | 819 | 0.140 |
Why?
|
| Obesity | 2 | 2018 | 1061 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 87 | 0.140 |
Why?
|
| Bevacizumab | 1 | 2019 | 255 | 0.140 |
Why?
|
| Primary Cell Culture | 2 | 2016 | 84 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 1302 | 0.140 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 198 | 0.140 |
Why?
|
| RNA | 1 | 2022 | 595 | 0.140 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2024 | 30 | 0.130 |
Why?
|
| Cysteine Proteases | 1 | 2017 | 4 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 271 | 0.130 |
Why?
|
| Cells | 1 | 2017 | 30 | 0.130 |
Why?
|
| Binding Sites | 8 | 2002 | 1159 | 0.130 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1604 | 0.130 |
Why?
|
| Enzyme Assays | 1 | 2017 | 23 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 211 | 0.130 |
Why?
|
| Plasminogen Activators | 1 | 1997 | 10 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 261 | 0.130 |
Why?
|
| Receptors, Prolactin | 1 | 2017 | 11 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 212 | 0.130 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2018 | 132 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2019 | 315 | 0.120 |
Why?
|
| Embryo Implantation | 2 | 2023 | 24 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2008 | 133 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 321 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 237 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 41 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 122 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 233 | 0.120 |
Why?
|
| Endothelial Cells | 4 | 2019 | 500 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2021 | 594 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 3 | 2018 | 212 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2007 | 285 | 0.120 |
Why?
|
| fas Receptor | 2 | 2021 | 73 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 68 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2016 | 90 | 0.120 |
Why?
|
| Peritoneal Cavity | 1 | 2015 | 19 | 0.120 |
Why?
|
| Protease Inhibitors | 3 | 2021 | 71 | 0.120 |
Why?
|
| Carbon | 1 | 2016 | 99 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 461 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2019 | 601 | 0.120 |
Why?
|
| Organ Culture Techniques | 1 | 2015 | 120 | 0.120 |
Why?
|
| Phylogeny | 2 | 2016 | 1339 | 0.110 |
Why?
|
| Exosomes | 1 | 2016 | 66 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2019 | 667 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 446 | 0.110 |
Why?
|
| Software | 1 | 2019 | 693 | 0.110 |
Why?
|
| Escin | 1 | 2015 | 1 | 0.110 |
Why?
|
| Prochlorperazine | 1 | 2015 | 1 | 0.110 |
Why?
|
| Tomatine | 1 | 2015 | 1 | 0.110 |
Why?
|
| Cantharidin | 1 | 2015 | 2 | 0.110 |
Why?
|
| Male | 12 | 2025 | 47075 | 0.110 |
Why?
|
| Biguanides | 1 | 2015 | 5 | 0.110 |
Why?
|
| Benzophenanthridines | 1 | 2015 | 23 | 0.110 |
Why?
|
| Adenosine | 1 | 2018 | 291 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 61 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2015 | 58 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2012 | 1527 | 0.110 |
Why?
|
| Risk Factors | 3 | 2021 | 6232 | 0.110 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2014 | 5 | 0.110 |
Why?
|
| Niclosamide | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cell Line | 6 | 2009 | 2483 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 1997 | 419 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 77 | 0.110 |
Why?
|
| Integrins | 1 | 2014 | 81 | 0.100 |
Why?
|
| Uterine Neoplasms | 2 | 2010 | 289 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2015 | 186 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 94 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 92 | 0.100 |
Why?
|
| Macrophages, Peritoneal | 1 | 2014 | 25 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2014 | 128 | 0.100 |
Why?
|
| Arsenates | 1 | 2013 | 1 | 0.100 |
Why?
|
| Chicago | 2 | 2024 | 1513 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-raf | 4 | 1997 | 51 | 0.100 |
Why?
|
| Cross-Cultural Comparison | 1 | 1993 | 36 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 151 | 0.100 |
Why?
|
| Genes, Reporter | 3 | 2001 | 276 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2025 | 516 | 0.100 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 191 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2025 | 9711 | 0.100 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 399 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 650 | 0.090 |
Why?
|
| Young Adult | 3 | 2021 | 7507 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2012 | 31 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 707 | 0.090 |
Why?
|
| Estrogens | 2 | 2009 | 201 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 47 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2015 | 489 | 0.090 |
Why?
|
| Enzyme Induction | 3 | 2016 | 83 | 0.090 |
Why?
|
| Gonadoblastoma | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dysgerminoma | 1 | 2011 | 7 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2012 | 176 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 159 | 0.090 |
Why?
|
| SOX9 Transcription Factor | 1 | 2011 | 31 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 382 | 0.080 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2011 | 19 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2011 | 239 | 0.080 |
Why?
|
| Pregnancy | 5 | 2024 | 3244 | 0.080 |
Why?
|
| Ovarian Cysts | 1 | 2011 | 15 | 0.080 |
Why?
|
| Taxoids | 1 | 2011 | 127 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 1129 | 0.080 |
Why?
|
| HMGA2 Protein | 2 | 2007 | 15 | 0.080 |
Why?
|
| Sequence Deletion | 2 | 2009 | 207 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2010 | 70 | 0.080 |
Why?
|
| Mast Cells | 1 | 2011 | 97 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 403 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 183 | 0.080 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 97 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2007 | 80 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2011 | 126 | 0.080 |
Why?
|
| Mullerian Ducts | 1 | 2009 | 21 | 0.080 |
Why?
|
| Chronic Disease | 1 | 1993 | 984 | 0.080 |
Why?
|
| Pelvic Pain | 1 | 2011 | 88 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 159 | 0.080 |
Why?
|
| Gonadotropins | 1 | 2009 | 32 | 0.080 |
Why?
|
| Protein Isoforms | 2 | 2021 | 303 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 4 | 1997 | 682 | 0.080 |
Why?
|
| Ascites | 2 | 2023 | 55 | 0.080 |
Why?
|
| Ovarian Diseases | 1 | 2009 | 28 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2011 | 674 | 0.070 |
Why?
|
| Adolescent | 2 | 2021 | 10079 | 0.070 |
Why?
|
| Integrases | 1 | 2009 | 68 | 0.070 |
Why?
|
| Trophoblasts | 1 | 2009 | 36 | 0.070 |
Why?
|
| Child | 1 | 2021 | 7681 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2011 | 174 | 0.070 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 58 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 640 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2011 | 318 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2013 | 503 | 0.070 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2008 | 14 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 324 | 0.070 |
Why?
|
| Cattle | 1 | 2009 | 397 | 0.070 |
Why?
|
| Liver | 2 | 2005 | 1231 | 0.070 |
Why?
|
| Abdominal Cavity | 1 | 2008 | 17 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2009 | 161 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 184 | 0.070 |
Why?
|
| Receptor, PAR-1 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1995 | 1105 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 2555 | 0.070 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 10 | 0.070 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 28 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 24 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 279 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 1103 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 47 | 0.070 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 3 | 1996 | 26 | 0.070 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2007 | 10 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 2 | 2005 | 24 | 0.060 |
Why?
|
| Thyroid Neoplasms | 2 | 2005 | 469 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 12 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2007 | 157 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2018 | 278 | 0.060 |
Why?
|
| DNA | 3 | 2004 | 1274 | 0.060 |
Why?
|
| Time Factors | 5 | 2018 | 5567 | 0.060 |
Why?
|
| Phenotype | 4 | 2019 | 2638 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3605 | 0.060 |
Why?
|
| Antibodies | 1 | 2008 | 348 | 0.060 |
Why?
|
| Genes, jun | 2 | 1996 | 18 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 77 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2020 | 39 | 0.060 |
Why?
|
| Paraffin Embedding | 2 | 2020 | 77 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2008 | 234 | 0.060 |
Why?
|
| Mutagenesis | 2 | 2015 | 195 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2002 | 2023 | 0.060 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2005 | 12 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1284 | 0.060 |
Why?
|
| Cell Division | 5 | 2012 | 689 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 316 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2025 | 16 | 0.060 |
Why?
|
| Breast | 1 | 2007 | 315 | 0.050 |
Why?
|
| Chemokine CXCL13 | 1 | 2025 | 19 | 0.050 |
Why?
|
| Brain Stem Neoplasms | 1 | 2005 | 21 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 700 | 0.050 |
Why?
|
| Sarcoma | 1 | 2006 | 222 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2004 | 107 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2024 | 39 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2005 | 148 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2004 | 157 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2025 | 117 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 400 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2008 | 447 | 0.050 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2004 | 2 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 135 | 0.050 |
Why?
|
| Dactinomycin | 1 | 2004 | 32 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2025 | 121 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2007 | 673 | 0.050 |
Why?
|
| Postnatal Care | 1 | 2024 | 32 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2006 | 200 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2024 | 72 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2006 | 418 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 403 | 0.050 |
Why?
|
| Hypoxia | 1 | 2009 | 699 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 207 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 581 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 111 | 0.050 |
Why?
|
| Phthalazines | 1 | 2024 | 58 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2004 | 353 | 0.050 |
Why?
|
| Methotrexate | 1 | 2004 | 227 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 2001 | 239 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2023 | 36 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2024 | 169 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 238 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2019 | 721 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2004 | 163 | 0.050 |
Why?
|
| Proteins | 3 | 2004 | 804 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 50 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 428 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 323 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 831 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2007 | 66 | 0.050 |
Why?
|
| Laser Capture Microdissection | 1 | 2022 | 20 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1950 | 0.050 |
Why?
|
| Delivery, Obstetric | 1 | 2023 | 120 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2023 | 81 | 0.050 |
Why?
|
| Piperazines | 1 | 2024 | 306 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2025 | 386 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 112 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 440 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2012 | 4025 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 4823 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2023 | 221 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2005 | 977 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2002 | 993 | 0.040 |
Why?
|
| Gastrins | 1 | 2001 | 15 | 0.040 |
Why?
|
| Transcription Factor AP-2 | 3 | 2007 | 13 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 162 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2025 | 358 | 0.040 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2021 | 3 | 0.040 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2021 | 4 | 0.040 |
Why?
|
| Receptors, Vitronectin | 1 | 2001 | 5 | 0.040 |
Why?
|
| Nuclear Proteins | 3 | 2002 | 750 | 0.040 |
Why?
|
| Pancreatic Elastase | 1 | 2021 | 15 | 0.040 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2001 | 18 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2021 | 57 | 0.040 |
Why?
|
| Telemedicine | 1 | 2024 | 250 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2021 | 76 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2005 | 560 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2001 | 114 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2001 | 45 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2025 | 481 | 0.040 |
Why?
|
| Reperfusion | 1 | 2001 | 33 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 238 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1782 | 0.040 |
Why?
|
| Luciferases | 1 | 2001 | 128 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2001 | 107 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2001 | 74 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 1997 | 41 | 0.040 |
Why?
|
| Proteolysis | 1 | 2021 | 129 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 169 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2001 | 169 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2001 | 153 | 0.040 |
Why?
|
| Succinate-CoA Ligases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Flavonoids | 2 | 1997 | 86 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 447 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2002 | 423 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2019 | 139 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 52 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 58 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 592 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 11 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2011 | 2681 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2001 | 484 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 28 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 446 | 0.040 |
Why?
|
| Niacinamide | 1 | 2019 | 105 | 0.040 |
Why?
|
| Protein Precursors | 1 | 1999 | 133 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 182 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2019 | 40 | 0.040 |
Why?
|
| Placenta | 1 | 2000 | 203 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2018 | 14 | 0.040 |
Why?
|
| Sphingosine | 1 | 2019 | 73 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 73 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2019 | 123 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 1567 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2011 | 523 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 227 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 218 | 0.030 |
Why?
|
| Tretinoin | 1 | 1998 | 130 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 356 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2018 | 102 | 0.030 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 1997 | 17 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2018 | 131 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2000 | 270 | 0.030 |
Why?
|
| Protein Phosphatase 1 | 1 | 1997 | 31 | 0.030 |
Why?
|
| Vanadates | 1 | 1997 | 32 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2017 | 93 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1997 | 47 | 0.030 |
Why?
|
| Placental Lactogen | 1 | 2017 | 13 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 36 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 373 | 0.030 |
Why?
|
| Prolactin | 1 | 2017 | 90 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2018 | 218 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2016 | 30 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 393 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2018 | 238 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2529 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1998 | 165 | 0.030 |
Why?
|
| Oncogene Proteins v-fos | 1 | 1996 | 3 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 50 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2001 | 123 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 84 | 0.030 |
Why?
|
| Immediate-Early Proteins | 1 | 1997 | 161 | 0.030 |
Why?
|
| Endocytosis | 1 | 2017 | 187 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2017 | 239 | 0.030 |
Why?
|
| Metabolome | 1 | 2016 | 70 | 0.030 |
Why?
|
| Phenformin | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2015 | 15 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 169 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 374 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 119 | 0.030 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 1995 | 25 | 0.030 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2012 | 1646 | 0.030 |
Why?
|
| Cyclin E | 1 | 2015 | 28 | 0.030 |
Why?
|
| Codon | 1 | 1995 | 116 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 525 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2001 | 98 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2015 | 95 | 0.030 |
Why?
|
| Cisplatin | 2 | 2008 | 578 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2011 | 615 | 0.030 |
Why?
|
| Trypsin | 1 | 1995 | 92 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 123 | 0.030 |
Why?
|
| Protein Kinases | 1 | 1996 | 212 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 68 | 0.030 |
Why?
|
| Mifepristone | 1 | 2015 | 56 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 66 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1995 | 280 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 311 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 125 | 0.030 |
Why?
|
| Epitopes | 1 | 1995 | 258 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2005 | 74 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 327 | 0.030 |
Why?
|
| Lovastatin | 1 | 2014 | 28 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2015 | 156 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 159 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 191 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 187 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 162 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 191 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 258 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 218 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 304 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 105 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 548 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 139 | 0.020 |
Why?
|
| Hungary | 1 | 1993 | 3 | 0.020 |
Why?
|
| Multiphasic Screening | 1 | 1993 | 1 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2001 | 1235 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 1895 | 0.020 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 38 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 45 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2012 | 32 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 102 | 0.020 |
Why?
|
| Vagina | 1 | 1993 | 186 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 2002 | 45 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 720 | 0.020 |
Why?
|
| DNA Primers | 2 | 2004 | 530 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 25 | 0.020 |
Why?
|
| CHO Cells | 2 | 2002 | 188 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 1993 | 193 | 0.020 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1995 | 401 | 0.020 |
Why?
|
| Cricetinae | 2 | 2002 | 533 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 282 | 0.020 |
Why?
|
| Cytoplasm | 2 | 2002 | 276 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 306 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 95 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 220 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 72 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 47 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 388 | 0.020 |
Why?
|
| Gelatinases | 2 | 2001 | 10 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2005 | 2457 | 0.020 |
Why?
|
| Metalloendopeptidases | 2 | 2001 | 44 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 129 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 332 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 31 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2009 | 48 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 114 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 137 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1782 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2009 | 52 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2001 | 679 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2008 | 47 | 0.020 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Incidence | 1 | 1993 | 1779 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 396 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 1211 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2008 | 163 | 0.020 |
Why?
|
| Aging | 1 | 1993 | 770 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 448 | 0.020 |
Why?
|
| Suppression, Genetic | 1 | 2007 | 30 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 1999 | 94 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 412 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2007 | 111 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2007 | 176 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2006 | 27 | 0.020 |
Why?
|
| Reference Values | 2 | 2001 | 608 | 0.020 |
Why?
|
| Femur Head | 1 | 2006 | 8 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 66 | 0.010 |
Why?
|
| Glioma | 1 | 2009 | 309 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 57 | 0.010 |
Why?
|
| Ilium | 1 | 2006 | 32 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 264 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 98 | 0.010 |
Why?
|
| Neutropenia | 1 | 2006 | 211 | 0.010 |
Why?
|
| Sacrum | 1 | 2006 | 82 | 0.010 |
Why?
|
| Neoplasms, Bone Tissue | 1 | 2005 | 2 | 0.010 |
Why?
|
| Calcitonin | 1 | 2005 | 41 | 0.010 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 479 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2006 | 194 | 0.010 |
Why?
|
| Mediastinum | 1 | 2005 | 42 | 0.010 |
Why?
|
| Anemia | 1 | 2006 | 135 | 0.010 |
Why?
|
| Rats | 2 | 2001 | 4071 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2005 | 73 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1995 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 113 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2004 | 76 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 194 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 889 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 285 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2011 | 4001 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 435 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 839 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 1751 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 142 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 310 | 0.010 |
Why?
|
| Vesicular Biogenic Amine Transport Proteins | 1 | 2001 | 2 | 0.010 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2001 | 3 | 0.010 |
Why?
|
| Chromogranin A | 1 | 2001 | 8 | 0.010 |
Why?
|
| Histidine Decarboxylase | 1 | 2001 | 6 | 0.010 |
Why?
|
| Enterochromaffin Cells | 1 | 2001 | 3 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2001 | 20 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 2666 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2001 | 54 | 0.010 |
Why?
|
| Chromogranins | 1 | 2001 | 17 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2001 | 112 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2001 | 46 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2001 | 31 | 0.010 |
Why?
|
| Platelet Activation | 1 | 2001 | 18 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 39 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2001 | 219 | 0.010 |
Why?
|
| HELLP Syndrome | 1 | 2000 | 8 | 0.010 |
Why?
|
| Guanosine Diphosphate | 1 | 2000 | 18 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2001 | 230 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 2000 | 36 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2001 | 245 | 0.010 |
Why?
|
| Breast Diseases | 1 | 2000 | 101 | 0.010 |
Why?
|
| Monocytes | 1 | 2001 | 219 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 731 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 1009 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 1998 | 18 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 1998 | 17 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1998 | 24 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1998 | 76 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 358 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1998 | 77 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1998 | 63 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1998 | 201 | 0.010 |
Why?
|
| DNA Footprinting | 1 | 1997 | 16 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 267 | 0.010 |
Why?
|
| Collagen | 1 | 1998 | 313 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1996 | 126 | 0.010 |
Why?
|
| Recurrence | 1 | 1999 | 1254 | 0.010 |
Why?
|
| Keratin-10 | 1 | 1993 | 1 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1998 | 467 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1993 | 26 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1993 | 40 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2000 | 2558 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1993 | 910 | 0.000 |
Why?
|